• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD Back to Search Results
Catalog Number UNK ABSORB
Device Problem Patient-Device Incompatibility (2682)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 03/01/2018
Event Type  malfunction  
Manufacturer Narrative
Date of event, implant date: dates estimated.Unique device identifier (udi#): in the absence of a reported part number, the udi cannot be calculated.The device was not returned for evaluation.A review of the lot history record and complaint history could not be conducted because the part and lot numbers were not provided.Based on the information reviewed, a conclusive cause for the reported difficulties could not be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The additional adverse patient effects referenced are being filed under a separate medwatch report #.The absorb device is currently not commercially available in the u.S; however, it is similar to a device sold in the u.S.Article titled: "serial baseline, 12-, 24-, and 60-month optical coherence tomography evaluation of st segment elevation myocardial infarction patients treated with absorb bioresorbable vascular scaffold"na.
 
Event Description
It was reported through a research article identifying absorb bioresorbable scaffolds that may be related to the following: stent malposition, stenosis, thrombosis, and target vessel revascularization.Details are listed in the article, titled "serial baseline, 12-, 24-, and 60-month optical coherence tomography evaluation of st segment elevation myocardial infarction patients treated with absorb bioresorbable vascular scaffold".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE SCAFFOLD
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, REG # 2024168
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
lindsey bell
26531 ynez rd.
temecula, CA 92591-4628
9519143996
MDR Report Key12321622
MDR Text Key266623500
Report Number2024168-2021-07162
Device Sequence Number1
Product Code PNY
Combination Product (y/n)Y
Reporter Country CodePL
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physician
Type of Report Initial
Report Date 08/13/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/13/2021
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK ABSORB
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/05/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Age55 YR
-
-